Forxiga® - Diabetes

General information

From September 1st 2021 onwards, Forxiga® (dapagliflozine) 10 mg for the treatment of adults with type 2 diabetes mellitus with a very high risk of cardiovascular disease is fully reimbursed by the health insurer.             

With this reimbursement, the Reimbursement Solution TerugBetaalRegeling (TBR) of Forxiga® (dapagliflozin) 10 mg for patients with diabetes and a very high risk of cardiovascular disease will expire on 1 September 2021. For patients who do NOT fall under these new reimbursement conditions, a decision will be made in 6 months on the continuation and implementation of the current TBR and the current TBR will continue to apply.

Very high risk means:
• previously proven cardiovascular disease; and/or
• chronic kidney damage with
− eGFR 30-59 ml/min per 1.73m2 with moderately elevated albuminuria (ACR > 3 mg/mmol/l); or
− eGFR ≥ 60 ml/min per 1.73 m2 with severely elevated albuminuria (ACR>30 mg/mmol)

From November 1st 2021, an extra group of patients with type 2 diabetes mellitus and CKD, with an eGFR between 30 and 44 ml/min per 1,73m² and without albuminuria, is fully reimbursed.

^{(NL-8239 exp.date 08/11/23)}     

For a complete reimbursment overview of Forxiga® (dapagliflozine) 10 mg, click here. 

For a digital reimbursement guide of Forxiga® (dapagliflozine) 10 mg, click here.